GROSSI, FRANCESCO

GROSSI, FRANCESCO  

DIPARTIMENTO DI MEDICINA E CHIRURGIA  

Mostra records
Risultati 1 - 20 di 254 (tempo di esecuzione: 0.053 secondi).
Titolo Data di pubblicazione Autore(i) File
30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT) 1-gen-2018 de Marinis, Filippo; Ciardiello, Fortunato; Baas, Paul; Crinò, Lucio; Giaccone, Giuseppe; Grossi, Francesco; Hellmann, Matthew D; Mok, Tony S K; Lena, Hervè; Paz-Ares, Luis; Rodriguez-Abreu, Delvys; Von Pavel, Joachim; Gridelli, Cesare
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer 1-gen-2001 Sobrero, A; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, Gl; Aschele, C; Ravaioli, A; Testore, P; Caroti, C; Gallo, L; Pessi, Ma; Cortesi, E; Turci, D; Grossi, F; Labianca, R
A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer 1-gen-2012 Nuijten, Mjc; Carpeno, Jd; Chouaid, C; Vergnenegre, A; Grossi, F; Bischoff, H; Heigener, D; Walzer, S
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer 1-gen-2012 Grossi, F; de Marinis, F; Gebbia, V; Riccardi, F; Caffo, O; Gamucci, T; Ferrau, F; Nardi, M; Moscetti, L; Boni, L; Dondi, D; Galligioni, E
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) 1-gen-2013 Groen, Hj; Socinski, Ma; Grossi, F; Juhasz, E; Gridelli, C; Baas, P; Butts, Ca; Chmielowska, E; Usari, T; Selaru, P; Harmon, C; Williams, Ja; Gao, F; Tye, L; Chao, Rc; Blumenschein GR, Jr
Adjuvant chemotherapy for non-small cell lung cancer: Ready for clinical practice? 1-gen-2006 Tiseo, M; Franciosi, V; Grossi, F; Ardizzoni, A
Adjuvant pembrolizumab for melanoma: update from the EORTC 1325-MG/KEYNOTE-054 trial 1-gen-2021 Indini, A.; Grossi, F.
Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study 1-gen-2022 Jin, Kai-Qi; Liu, Xiao-Gang; Guo, Yan-Hua; Wu, Chun-Xiao; Dai, Jie; Li, Jia-Qi; Minervini, Fabrizio; Antonoff, Mara B; Friedlaender, Alex; Addeo, Alfredo; Kocher, Gregor J; Grossi, Francesco; Zhu, Yu-Ming; Zhang, Peng; Jiang, Ge-Ning
Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study 1-gen-2014 Gridelli, C; de Marinis, F; Ardizzoni, A; Novello, S; Fontanini, G; Cappuzzo, F; Grossi, F; Santo, A; Cortinovis, D; Favaretto, A; Lorusso, V; Galetta, D; Siena, S; Bettini, A; Iurlaro, M; Caprioli, A; LIFE study, Team
Advances in treatment of mesothelioma 1-gen-2016 Maggioni, C; Barletta, G; Rijavec, E; Biello, F; Gualco, E; Grossi, F
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial 1-gen-2016 Schuler, M; Yang, Jc; Park, K; Kim, Jh; Bennouna, J; Chen, Ym; Chouaid, C; De Marinis, F; Feng, Jf; Grossi, F; Kim, Dw; Liu, X; Lu, S; Strausz, J; Vinnyk, Y; Wiewrodt, R; Zhou, C; Wang, B; Chand, Vk; Planchard, D; LUX-Lung, 5 Investigators
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer 1-gen-2018 Tagliamento, M.; Genova, C.; Rijavec, E.; Rossi, G.; Biello, F.; Dal Bello, M. G.; Alama, A.; Coco, S.; Boccardo, S.; Grossi, F.
Afatinib for the treatment of advanced non-small-cell lung cancer 1-gen-2014 Genova, C; Rijavec, E; Barletta, G; Burrafato, G; Biello, F; Dal Bello, Mg; Coco, S; Truini, A; Alama, A; Boccardo, F; Grossi, F
Afatinib for the treatment of non-small cell lung cancer 1-gen-2015 Biello, F.; Maggioni, C.; Rijavec, E.; Genova, C.; Barletta, G.; Gualco, E.; Truini, A.; Coco, S.; Dal Bello, M. G.; Vanni, I.; Alama, A.; Boccardo, F.; Grossi, F.
Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-to-mesenchymal transition 1-gen-2015 Coco, S; Truini, Anna; Alama, A; Dal Bello, Mg; Venè, R; Garuti, Anna; Carminati, ENRICO GIANNI; Rijavec, E; Genova, Carlo; Barletta, G; Sini, C; Ballestrero, Alberto; Boccardo, Francesco; Grossi, Francesco
Alternating bolus and continuous infusion 5-fluorouracil: A strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients 1-gen-1996 Guglielmi, A; Aschele, C; Grossi, F; Tixi, L; Sobrero, A
An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy 1-gen-2009 Tiseo, M; Gridelli, C; Cascinu, S; Crino, L; Piantedosi, Fv; Grossi, F; Brandes, Aa; Labianca, R; Siena, S; Amoroso, D; Belvedere, O; Valentino, B; Bearz, A; Venturino, P; Ardizzoni, A
Analysis of K-ras, p53, bcl-2 and Rb expression in non-small cell lung cancer cell lines. 1-gen-1997 Loprevite, M.; Varesco, L.; Favoni, R.; Ferrara, G.; Moro, F.; Ottaggio, L.; Fronza, G.; Campomenosi, Paola; Abbondandolo, A.; Cutrona, G.; Roncella, S.; Albini, A.; Aluigi, M.; Pozzi, S.; Pera, C.; Biticchi, R.; Gismondi, V.; Grossi, F.; Pennucci, M.; Ardizzoni, A.
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols 1-gen-2011 Bello, C; Dal Bello, G; Cea, M; Nahimana, A; Aubry, D; Garuti, A; Motta, G; Moran, E; Fruscione, F; Pronzato, P; Grossi, F; Patrone, F; Ballestrero, A; Dupuis, M; Sordat, B; Zimmermann, K; Loretan, J; Wartmann, M; Duchosal, Ma; Nencioni, A; Vogel, P
The appropriateness of invasive ventilation in covid-19 positive cancer patients: Proposal of a new prognostic score 1-gen-2021 Ghidini, M.; Indini, A.; Rijavec, E.; Bareggi, C.; Cattaneo, M.; Tomasello, G.; Galassi, B.; Gambini, D.; Grossi, F.